+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis

Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis

American Journal of Hematology 69(1): 72-73

Heparin-induced thrombocytopenia (HIT), characterized by the formation of antibodies to a complex of platelet factor 4 (PF4) and heparin, is a well-recognized risk factor for thromboembolic complications. The frequency of antibody development varies among patient populations. Hemodialysis patients have repeated heparin exposure and should be at risk of developing HIT. This might, contribute to the development of vascular access thrombosis. We prospectively evaluated 88 hemodialysis patients for the presence of anti-PF4/heparin antibodies. Eighteen patients (20%) had a prior history of 1 or more prior access thrombosis. One patient (1.14%), without a history of graft thrombosis, tested positive for anti-PF4/heparin antibodies. In our study, the presence of anti-PF4/heparin antibodies was rare and was not increased in patients with a history of vascular access thrombosis.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 010682300

Download citation: RISBibTeXText

PMID: 11835336

DOI: 10.1002/ajh.10032

Related references

The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thrombosis Research 120(2): 215-220, 2006

Preliminary analysis of the prevalence of anti-heparin antibodies in hemodialysis patients with vascular access related thrombosis. Blood 98(11 Part 2): 100b-101b, November 16, 2001

Anti-heparin-platelet factor 4 antibody is a risk factor for vascular access obstruction in patients undergoing hemodialysis. Journal of Korean Medical Science 18(1): 69-72, 2003

The prevalence of heparin-induced thrombocytopenia and of heparin-dependent anti-platelet antibodies using platelet factor 4 /heparin ELISA in hemodialysis patients Multicenter study. Journal of the American Society of Nephrology 7(9): 1489, 1996

Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis. Thrombosis and Haemostasis 75(4): 695-696, 1996

Anti-cardiolipin, anti-endothelial-cell and anti-malonyldialdehyde-LDL antibodies in uremic patients undergoing hemodialysis Relationship with vascular access thrombosis and thromboembolic events. Lupus 7(SUPPL 2): S214, 1998

Anti-cardiolipin, anti-endothelial-cell and anti-malondialdehyde-LDL antibodies in uremic patients undergoing hemodialysis: relationship with vascular access thrombosis and thromboembolic events. Human Antibodies 9(2): 125-131, 1999

Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 89(2): 370-375, 1997

Frequency of Heparin-Platelet Factor 4 Antibodies in Patients Presenting to the Emergency Room with Symptoms of Thrombosis. Blood 100(11): Abstract No 2709, November 16, 2002

Frequency of heparin-platelet factor 4 antibodies in patients presenting to the Emergency Department with symptoms of thrombosis. Blood 102(11): 549a, November 16, 2003

Anti-heparin-platelet factor 4 antibodies are associated with arterial and venous thrombosis in patients with maintenance haemodialysis. Thrombosis and Haemostasis 102(6): 1282-1284, 2010

Heparin-platelet-factor-4-antibodies and heparin-induced platelet aggregation Incidence of positive test results without clinical symptoms in patients after vascular surgery. Annals of Hematology 76(SUPPL 1): A58, 1998

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 91(3): 916-922, 1998

Recurrent vascular access thrombosis in hemodialysis patients lack of demonstrable blood hypercoagulability. Haemostasis 16(SUPPL 5): 55, 1986

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. Journal of Clinical Investigation 93(1): 81-88, 1994